Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/62806
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDeane, A.-
dc.contributor.authorChapman, M.-
dc.contributor.authorHorowitz, M.-
dc.date.issued2010-
dc.identifier.citationCritical Care (UK), 2010; 14(5):1-3-
dc.identifier.issn1466-609X-
dc.identifier.issn1466-609X-
dc.identifier.urihttp://hdl.handle.net/2440/62806-
dc.descriptionCommentary-
dc.description.abstractGlucagon-like peptide-1 (GLP-1), a principal mediator of the postprandial insulinotropic response in health, has a half-life of minutes. The saliva of the Gila monster contains exendin-4, a structural analogue of human GLP-1, but with a much longer half-life. A synthetic preparation of exendin-4, exenatide, is suitable for human use and effectively lowers glucose in ambulant type 2 diabetic patients. When compared with insulin, exenatide therapy is associated with a reduction in hypoglycaemic episodes and postprandial glycaemic excursions in this group. Accordingly, GLP-1 analogues are appealing therapies for hyperglycaemia in the critically ill patient and warrant further study.-
dc.description.statementofresponsibilityAdam M Deane, Marianne J Chapman and Michael Horowitz-
dc.language.isoen-
dc.publisherCurrent Science Ltd-
dc.rights© 2010 BioMed Central Ltd-
dc.subjectVenoms-
dc.subjectAnimals-
dc.subjectHumans-
dc.subjectLizards-
dc.subjectReptilian Proteins-
dc.subjectGlucagon-Like Peptide 1-
dc.titleThe therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill-
dc.typeJournal article-
dc.identifier.doi10.1186/cc9281-
pubs.publication-statusPublished-
dc.identifier.orcidDeane, A. [0000-0002-7620-5577]-
dc.identifier.orcidChapman, M. [0000-0003-0710-3283]-
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]-
Appears in Collections:Anaesthesia and Intensive Care publications
Aurora harvest

Files in This Item:
File Description SizeFormat 
hdl_62806.pdfPublished version128.51 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.